Docetaxel in Combination With Doxorubicin and Cyclophosphamide As Adjuvant Treatment for Early Node-Positive Breast Cancer: A Cost-Effectiveness and Cost-Utility Analysis | Zendy

Sorrel Wolowacz | Zendy; David Cameron | Zendy; Helen Tate | Zendy; A Bagust | Zendy

Open Access

Docetaxel in Combination With Doxorubicin and Cyclophosphamide As Adjuvant Treatment for Early Node-Positive Breast Cancer: A Cost-Effectiveness and Cost-Utility Analysis

Author(s) -

Sorrel Wolowacz,

David Cameron,

Helen Tate,

A Bagust

Publication year - 2008

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2006.10.4190

Subject(s) - medicine , docetaxel , breast cancer , quality adjusted life year , regimen , cyclophosphamide , oncology , cost effectiveness , metastatic breast cancer , pound (networking) , surgery , chemotherapy , cancer , risk analysis (engineering) , world wide web , computer science

To estimate the cost effectiveness of TAC (docetaxel, doxorubicin, and cyclophosphamide) compared with FAC (fluorouracil, doxorubicin, and cyclophosphamide) when administered as adjuvant therapy to women with node-positive early breast cancer in the United Kingdom (UK), both with and without primary prophylaxis with granulocyte colony-stimulating factor (G-CSF).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research